Health & Wellness Today New York: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.

Press releases published on April 22, 2026

Apr. 22, 2026

Nations First Wellness Center Using Cats and Kittens for Animal-Assisted Therapy Opens

Indeterminate EIN Presswire

Apr. 22, 2026

57th Street Chiropractic Welcomes Everest Chiropractic Patients in Care Transition

Indeterminate EIN Presswire

Apr. 22, 2026

Caring for the Human Spirit Conference Keynote Features 'Soul Making for the Caregiver'

Indeterminate EIN Presswire

Apr. 22, 2026

Rehavior Applauds Gateway Rehab’s Telehealth Milestone

Indeterminate EIN Presswire

Apr. 22, 2026

VNS Health Recognized for Gold Standard Evidence-Based Home Health Heart Failure Care

Indeterminate EIN Presswire

Apr. 22, 2026

Center for Family Services of Palm Beach County Appoints New Chief Development Officer

Indeterminate EIN Presswire

Apr. 22, 2026

FloatR Expands Workforce Engine for Phlebotomists and Specimen Collection, Launches New Offerings and v7 Platform

Indeterminate EIN Presswire

Apr. 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Indeterminate GlobeNewswire

Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire

Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire

Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire

Apr. 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Indeterminate GlobeNewswire

Apr. 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire

Apr. 22, 2026

Sight Sciences Announces the Release of its Sustainability Report

Indeterminate GlobeNewswire

Apr. 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

Indeterminate GlobeNewswire

Apr. 22, 2026

Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5

Indeterminate GlobeNewswire

Apr. 22, 2026

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Indeterminate GlobeNewswire

Apr. 22, 2026

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

Indeterminate GlobeNewswire

Apr. 22, 2026

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

Indeterminate GlobeNewswire